Browse > Article

Pharmacokinetics of Paclitaxel in Rabbits with Carbon Tetrachloride-Induced Hepatic Failure  

Choi, Jun-Shik (College of Pharmacy, Chosun University)
Publication Information
Archives of Pharmacal Research / v.25, no.6, 2002 , pp. 973-977 More about this Journal
Abstract
The pharmacokinetic of paclitaxel (1 mg/kg, i.v.) was investigated in rabbits with carbon tetrachloride-induced hepatic failure. The area under the plasma concentration-time curve (AUC) of paclitaxel was significantly (p<0.01) increased in severe carbon tetrachloride-induced hepatic failure rabbits ($1364.54{\pm}382.07$ ng/ml$\cdot$hr) compared to that of normal rabbits ($567.52{\pm}141.88$ ng/ml$\cdot$hr), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits ($803.1{\pm}208.81$ ng/ml$\cdot$hr). The volume of distribution (Vd) (6.25$\pm$1.56 L) and the elimination rate constant($\beta$) ($0.09{\pm}0.025{\;}hr^{-1}$) of paclitaxel in severe carbon tetrachloride-induced hepatic failure rabbits were significantly (p<0.05) decreased compared to those of normal rabbits ($11.65<{\pm}2.91$L, $0.12{\pm}0.030{\;}hr^{-1}$), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits ($9.46{\pm}2.37$ L, $0.10{\pm}0.026{\;}hr^{-1}$). Total body clearance ($CL_t$) of paclitaxel in severe carbon tetrachloride-induced hepatic failure rabbits ($0.733{\pm}0.183$ L/hr/kg) was significantly (p<0.01) decreased compared to that of normal rabbits ($1.762{\pm}0.440$ L/hr/kg), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits ($1.245{\pm}0.311$ L/hr/kg). The half-life(t1/2) of paclitaxel in severe carbon tetrachloride-induced hepatic failure rabbits ($7.71{\pm}2.16$ hr) was significantly (p<0.05) increased compared to that of normal rabbits ($5.75{\pm}1.44$hr), but not significantly in moderate carbon tetrachloride-induced hepatic failure rabbits ($6.77{\pm}1.76$hr). This results could be due to inhibition of paclitaxel metabolism in liver disorder rabbits since paclitaxel is essentially metabolized in liver. The findings suggest that the dosage regimen of paclitaxel should be adjusted when the drug would be administered in patients with liver disorder in a clinical situation.
Keywords
Paclitaxel; Pharmacokinetics; Carbon tetrachloride-induced hepatic failure;
Citations & Related Records

Times Cited By Web Of Science : 0  (Related Records In Web of Science)
Times Cited By SCOPUS : 2
연도 인용수 순위
1 Cresteil, T., Monsarrat, B., Alvinerie, P., Treluyer, J. M., Vieira, I. and Wright, M., Taxol metabolism by human liver microsomes: identifcation of cytochrome P450 isozymes involved in its biotramormation. Cancer. Res., 54, 386-392 (1994)   PUBMED
2 Kumar N., Taxol-induced polymerization of purified tubulin. Mechanism of action. J. Biol. Chem., 256, 10435-10441 (1991)
3 Nannan F'anday, V. R., Huizing, M. T., Willemse, Pax H. B., De Graeff, A., ten Bokkel Huinink, W. W., Vermorken, J. B. and Beijnier , J. H., Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Sem. Oncol., 24(supol 11), S11-34-S11-38 (1997)
4 Rahman, A., Korzekwa, K. R., Grogan, J., Gonzalezs, F. J. and Haris, J. W., Selective biotransformation of taxol to 6-hydroxytaxol by human cytochrome P450 2C8. Cancer Res., 54. 5543-5546 (1994)   PUBMED
5 Sparreboom, A., Van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K., Borst, P., Nooijen, W. J., Bejinen, J. H. and van Tellingen, O., Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by Pglycoprotein in the intestine. Proc. Natl. Acad. Sci. USA., 4, 2031-2035 (1997)
6 Walle, T., Walle, U. K., Kumar, G. N. and Bhalla, K. N., Taxol metabolism and disposition in cancer patients. Durg Metab. Disp., 23, 506-512 (1995)
7 Yamaoka, K., Tanigawara, Y., Nakagawa, T. and Uno, T., A pharmacokinetics analysis program for microcomputer. J. Pharm. Dyn., 4, 879-883 (1981)   DOI
8 Kumar G N., Walle, U. K. and Walle, T., Cytochrome P450 3A-mec iated human liver microsomal taxol 6-hydroxylation. J. Pharmacol. Exp. Ther., 268, 1160-1165 (1994)   PUBMED
9 Venook, A. P., Egorin, M. J., Rosner, G. L., Brown, T. D., Jahan, T. M., Batist, G., Hohl, R., Budman, D., Ratain, M. J., Kearns, C. M. and Schilsky, R. L., Phase and pharmacokinetic trial of paciltaxel in patients with hepatic dysfunction: cancer and leukemia group B 9264. J. Clin. Oncol., 16, 1811-1819 (1998)   DOI   PUBMED
10 Wiernik, P., Schwartz, E., Einzig, A., Strauman, J., Dutcher, J. P. and Lipton, R. B., Phasetrial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J. Clin. Oncol., 5, 1232-1239 (1987)   DOI   PUBMED
11 Sonnichsen, D. S., Hurwitz, C. A, Pratt, C. B., Shuster, J. J. and Reiling, M. V., Saturable pharmacokinetics and paclitaxel pharmacodynamics in child with solid tumors. J. Clin. Oncol., 12, 532-538 (1994)   DOI   PUBMED
12 Donel, M. G., Zucchetti, M., Munzone, E., Dlncalci, M. and Crosignani, A., Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur. J. Cancer., 34, 33-46 (1998)   DOI   ScienceOn
13 Manfe di, J. J. and Horwitz, S. B., An antimitotic agent with a new mechanism of action. Pharmacol. Ther. 25, 83-125 (1984)   DOI   ScienceOn
14 Rowinsky, E., Eisenhauer, E., Chaudhry, V., Arbuck, S. G. and Donehower, R. C., Clinical toxicities encountered with paclitaxel (Taxol (R)). Sem. Oncol. 20 Suppl., 3, 1-15 (1993)
15 McGui e, W. P., Rowinsky, E. K., Rosenheim, N. B., Grumbine, F. C., Ettinger, D. S. and Armstrong, D. K., Taxol: A unique antineoplasic agent with significant activity in advanced ovariar epithelial neoplasm. Ann. Intern. Med., 111, 273-279 (1999)
16 Van den Berg, H. W., Desai, Z. R., Wilson, R., Kennedy, G., Bridges, J. M. and Shanks, R G., The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother. Pharmacol., 8, 215-219 (1982)   DOI   PUBMED
17 Brown, T., Havlin, K., Weiss, G., Cagnola, J., Koeller, J., Kuhn, J., Rizzo, J., Craig, J., Phillips, J. and Von Hoff, D., A Phasetrial of taxol given by a 6-hour intravenous infusion. J. Clin. Oncol., 9, 1261-1267 (1991)   DOI   PUBMED
18 Gianni L. Kearns, C., Giani, A., Capri, G., Vigano, L., Locatelli, A., Etonadonna, A. and Egorin, M., Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokineticl pha macodynarnic relationships in humans. J. Clin. Oncol., 13, 180-190 (1995)   DOI   PUBMED
19 Mase, H., Hiraoka, M., Suzuki, A and Nakanomyo, H., Determination of New anticancer drug, Paclitaxel, in biological fluids by high performance liquid chromatography. Yakugaku Zasshi, 114, 351-355 (1994)   DOI   PUBMED
20 Sarosy, G., Kohn, E., Stone, D. A., Rothenberg, M., Jacob, J., Adamo, D. O., Ognibene, F. P., Cunnion, R. E. and Reed, E., Phasestudy of taxol and granulocyte stimulating factor in patients with refractory ovarian cancer. J. Clin. Oncol. , 10, 1165-1170 (1992)   DOI   PUBMED
21 Brenner, D. E., Wiernik, P. H., Wesley, M. and Bachur, N. R., Acute doxorubicin toxicity: Relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia. Cancer, 53, 1042-1048 (1984)   DOI   PUBMED   ScienceOn
22 Grem, J.L., Tutsch, K.D., Simon, K.J., Alberti, D.B., Willson, J., Tormiey, D., Swaminathan, S. and Trump ,D., Phasestudy of taxol administered as a short iv infusion daily for 5 days. Cancer. Treat. Rep., 71, 1179-1184 (1987)   PUBMED
23 Wiernik, P., Schwartz, E., Strauman, J., Dutcher, J. P., Lipton, R. B. and Paietta, E., Phaseclinical and pharmacokinetic study of taxol. Cancer Res., 47, 2486-2493 (1987)   PUBMED
24 Holmes, F. A., Walters, R. S., Theriault, R. L., Forman, A. D., Nevrton, L. K., Raber, M. N., Buzdar, A. U., Frye, D. K. and Hor obaqyi, G. N., Phase trial of taxol, an active drug in metastatic breast cancer. J. Natl. Cancer Inst., 83, 1797-1805 (1991)   PUBMED
25 Catalin, .J., Martin, N., Blachan, M. F. and Durand, A., Assay of paclitaxel (Taxol) in plasma and urine by high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci., 709, 281-288 (1998)   DOI   ScienceOn
26 Sonnichsen, D. S., Liu Q, Schuetz. E, G., Schuetz, J. D., Pappo, A. and Reiling, M. V, Variability in human cytochrome P450 paclitaxel metabolism. J. Pharmacol. Exp. Ther., 275, 566-575 (1995)   PUBMED
27 Wani, M. C., Taylor, H. L., Wall, M.E., Coggon, P. and McPhail, A. T., Plant antitumor agnets. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc., 93, 2325-2327 (1971)   DOI   PUBMED
28 Hirosh, F., Masaaki, O., Ayuko, T., Hideshi, M. and Hiroyuki, K., Pha macokinetics of Paclitaxel in experimental animals part 2. Tissue distribution. JPN. J. Cancer Chemother., 21, 659-664 (1994)
29 Rowin sky E. K., Cazenave, L. A and Donehower, R.C., Taxol: A nove investigational antimicrotubule agent. J. Natl. Cancer Inst., 82, 1247-1259 (1990)   DOI   PUBMED